LSTA

SEC Filing Summary: NeoStem, Inc. (Form 10-K)

Business Context and Reporting Period

Company: NeoStem, Inc. (formerly Phase III Medical, Inc.)
Reporting Period: Fiscal year ended December 31, 2007
Business Model: NeoStem operates a commercial autologous adult stem cell bank, providing collection, processing, and long-term storage services for future therapeutic use. The company manages a nationwide network of collection centers. In November 2007, the company expanded into research and development by acquiring Stem Cell Technologies, Inc. (SCTI), obtaining an exclusive worldwide license to VSEL (very small embryonic-like) stem cell technology from the University of Louisville.

Key Financial Metrics

Revenue Composition (2007): $41,000 from stem cell collection; $189,000 from startup fees for collection centers; $1,700 from the run-off of legacy warranty contracts (completed March 2007).
Financing Activities: Raised approximately $7.94 million in 2007 through private placements ($2.5 million) and a public offering ($6.35 million gross, $5.62 million net).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 407% year-over-year, driven by the expansion of the collection center network and startup fees, though absolute revenue remains low.
• Expense Surge: Selling, general, and administrative (SG&A) expenses increased 126% to $10.65 million. This was primarily due to a $2.98 million increase in stock-based compensation and a $1.65 million increase in stock/warrant issuances for services.
• Interest Expense Reduction: Interest expense dropped significantly from $1.37 million in 2006 to $22,000 in 2007, as convertible promissory notes were converted to equity or repaid.
• Liquidity Improvement: Working capital turned positive ($1.93 million) from a deficit in 2006, supported by successful capital raises.
• Strategic Acquisition: Acquired SCTI for 400,000 shares of common stock (valued at $940,000) to secure VSEL technology rights.

Guidance, Outlook, and Risks

Outlook: Management expects to incur additional operating losses and negative cash flow in the foreseeable future. The company requires substantial additional capital to fund R&D for VSEL technology, expand marketing, and meet contractual obligations. No specific revenue guidance was provided, but the goal is to generate significant revenue in 2008.

Key Risks:

• Liquidity: History of operating losses and dependence on future capital raises. Failure to secure funding could force delays in operations.
• Regulatory: The business operates in a highly regulated environment (FDA, state licenses). Failure to comply could halt operations.
• Market Acceptance: Success depends on the commercial viability of stem cell therapies and public acceptance of the service.
• Technology: VSEL technology is early-stage; there is no assurance it can be successfully commercialized or expanded to therapeutic quantities.
• Competition: Increasing competition from cord blood banks and other stem cell preservation companies.

Investor Verification Checklist

• Cash Runway: Verify current cash balance against the $2.02 million in contractual obligations (including $1.2 million in employment agreements and $275,000 in research commitments) to assess immediate liquidity risk.
• Revenue Quality: Confirm the sustainability of the $189,000 in startup fees versus recurring storage revenue, as the latter is currently minimal.
• Stock-Based Compensation: Review the impact of non-cash stock compensation ($4.59 million in 2007) on future dilution and expense recognition.
• VSEL Milestones: Monitor progress on the University of Louisville research agreement and the ability to meet diligence obligations to avoid license termination.
• Regulatory Status: Verify the status of biologics licenses in California and New York, and the licensing status of the New England Cryogenic Center (NECC) partnership.